GlassScriptPhysician profile
Mansoor S Zuberi
NPI 1972666568
$16,393.20
in general payments reported to CMS, 2019-2025
30 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 96% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,778 · 2020: $621 · 2021: $992 · 2022: $2,273 · 2023: $2,971 · 2024: $3,793 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,636 · Education: $93.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,635.85 |
| Education | $93.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,959.75 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,486.34 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,220.07 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $1,198.71 | 2019-2025 | Rexulti |
| Abbvie INC. | $1,152.88 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,074.48 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $990.86 | 2019-2025 | Hetlioz, Fanapt |
| Neurocrine Biosciences, INC. | $974.09 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $896.09 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $688.64 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $668.84 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $660.62 | 2019-2020 | |
| Neuronetics, INC. | $486.81 | 2019-2024 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $420.98 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $414.13 | 2024-2025 | Cobenfy |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $315.55 | 2019-2024 | |
| Bausch Health US, LLC | $314.08 | 2019-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $296.37 | 2023-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $219.20 | 2019-2024 | Dyanavel Xr |
| Indivior INC. | $183.22 | 2019-2025 | Sublocade, Perseris |
| Shire North American Group INC | $165.55 | 2019 | |
| Collegium Pharmaceutical, INC. | $118.26 | 2025 | Jornay Pm |
| Corium, LLC | $97.84 | 2022 | |
| Sunovion Pharmaceuticals INC. | $96.48 | 2019-2021 | |
| Biogen, INC. | $88.43 | 2025 | Zurzuvae |
| Avanir Pharmaceuticals, INC. | $74.42 | 2022 | |
| Merck Sharp & Dohme LLC | $62.66 | 2022-2023 | Belsomra |
| Adlon Therapeutics L.P. | $34.72 | 2019-2021 | |
| Neos Therapeutics, LP | $20.28 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.85 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mansoor Zuberi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.